A humanized antibody that binds to the interleukin 2 receptor.
Citations Over TimeTop 1% of 1989 papers
Abstract
The anti-Tac monoclonal antibody is known to bind to the p55 chain of the human interleukin 2 receptor and to inhibit proliferation of T cells by blocking interleukin 2 binding. However, use of anti-Tac as an immunosuppressant drug would be impaired by the human immune response against this murine antibody. We have therefore constructed a "humanized" antibody by combining the complementarity-determining regions (CDRs) of the anti-Tac antibody with human framework and constant regions. The human framework regions were chosen to maximize homology with the anti-Tac antibody sequence. In addition, a computer model of murine anti-Tac was used to identify several amino acids which, while outside the CDRs, are likely to interact with the CDRs or antigen. These mouse amino acids were also retained in the humanized antibody. The humanized anti-Tac antibody has an affinity for p55 of 3 x 10(9) M-1, about 1/3 that of murine anti-Tac.
Related Papers
- → Humanized Mik beta 1, a humanized antibody to the IL-2 receptor beta -chain that acts synergistically with humanized anti-TAC.(1993)48 cited
- → Human Anti–HIV-1 gp120 Monoclonal Antibodies with Neutralizing Activity Cloned from Humanized Mice Infected with HIV-1(2018)7 cited
- → NONHUMAN PRIMATE RESPONSES TO MURINE AND HUMANIZED OKT4A(1993)23 cited
- Biological activity of two humanized antibodies against two different breast cancer antigens and comparison to their original murine forms.(1995)
- → Clinical Results with Humanized and Human Monoclonal Antibodies(1994)1 cited